Evergreen Capital Management LLC Acquires 259 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Evergreen Capital Management LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,798 shares of the pharmaceutical company’s stock after acquiring an additional 259 shares during the quarter. Evergreen Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $1,357,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Quent Capital LLC grew its holdings in Vertex Pharmaceuticals by 4.5% during the 1st quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company’s stock worth $249,000 after acquiring an additional 22 shares during the last quarter. Advisor OS LLC lifted its position in shares of Vertex Pharmaceuticals by 4.4% in the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock worth $263,000 after purchasing an additional 23 shares during the period. Sculati Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals by 1.0% in the 4th quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company’s stock worth $1,029,000 after purchasing an additional 25 shares during the period. Avidian Wealth Enterprises LLC lifted its position in shares of Vertex Pharmaceuticals by 2.1% in the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock worth $594,000 after purchasing an additional 25 shares during the period. Finally, Strategic Blueprint LLC lifted its position in shares of Vertex Pharmaceuticals by 1.7% in the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock worth $726,000 after purchasing an additional 25 shares during the period. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Down 0.3%

Vertex Pharmaceuticals stock opened at $391.02 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88. The firm’s fifty day moving average is $433.35 and its 200 day moving average is $458.70. The company has a market capitalization of $100.25 billion, a PE ratio of 27.95 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the previous year, the company earned ($12.83) EPS. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on VRTX. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. JPMorgan Chase & Co. boosted their price target on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. HC Wainwright dropped their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. Leerink Partnrs downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 6th. Finally, William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $497.10.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.